Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021299 | 0.98 | SIGMAR1 (0.41) | SIGMAR1NOS3NOS1NOS2ADRA2A | |
| SCHEMBL31126014 | 0.95 | — | — | |
| SCHEMBL19059297 | 0.82 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL19059005 | 0.77 | — | — | |
| SCHEMBL13262088 | 0.74 | CYP11B2 (0.45) | NOS3TSHR | |
| SCHEMBL29043805 | 0.72 | — | — | |
| SCHEMBL2562162 | 0.71 | PNMT (0.43) | ADRA2AADRA2BADRA2CHTR2CCHRNB2 | |
| SCHEMBL2560588 | 0.71 | CHRNB2 (0.44) | ADRA2AADRA2BADRA2CHTR2CCHRNB2 | |
| SCHEMBL14844823 | 0.70 | FKBP5 (0.32) | — | |
| SCHEMBL13028729 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11641773-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-05-02 | — | — | US | claimed |
| US-11539007-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-12-27 | — | — | US | claimed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | claimed |
| US-20210159431-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-05-27 | — | — | US | claimed |
| US-20210119153-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-04-22 | — | — | US | claimed |
| US-10937973-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-03-02 | — | — | US | claimed |
| US-10894774-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2021-01-19 | — | — | US | claimed |
| US-10626090-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN INC. (US) | 2020-04-21 | — | — | US | claimed |
| EP-1487472-B1 | Treatment of ischemic or hypoxic conditions using heterocyclic carboxamides | FIBROGEN INC (US) | 2019-06-26 | — | — | EP | claimed |
| EP-2324834-B1 | Methods of Increasing Endogenous Erythropoietin (EPO) | FIBROGEN INC (US) | 2019-05-08 | — | — | EP | claimed |
| EP-1991544-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | VTV THERAPEUTICS LLC | 2007-08-16 | — | — | US | claimed |
| WO-2007089857-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| EP-0650961-B1 | Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments | HOECHST AG (DE) | 1997-03-05 | — | — | EP | claimed |
| EP-0650960-B1 | Substituted heterocyclic carboxylic acid amide esters, their preparation and their us as medicaments | HOECHST AG (DE) | 1997-03-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210159431-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | ORC3, LEF1, OCIAD1 | SIGMAR1 3149/4885NOS3 2270/4885NOS1 862/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | SIGMAR1 4108/4885NOS3 2811/4885NOS1 3541/4885 |
| US-11539007-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | SIGMAR1 3149/4885NOS3 2270/4885NOS1 862/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | SIGMAR1 4724/4885NOS3 424/4885NOS1 904/4885 |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | PTP4A1, PTPRJ, PTP4A2 | SIGMAR1 4460/4885NOS3 1241/4885NOS1 972/4885 |
| US-11641773-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | SIGMAR1 3149/4885NOS3 2270/4885NOS1 862/4885 |
| US-10626090-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | SIGMAR1 3564/4885NOS3 283/4885NOS1 395/4885 |
| US-10894774-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | SIGMAR1 4088/4885NOS3 460/4885NOS1 637/4885 |
| US-20210119153-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | ORC3, LEF1, OCIAD1 | SIGMAR1 3149/4885NOS3 2270/4885NOS1 862/4885 |
| US-10937973-B2 | Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | SIGMAR1 3149/4885NOS3 2270/4885NOS1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.